🇺🇸

Corporate Governance

· daily

US Executive Officer Management Changes SEC — March 27, 2026

Across 50 filings in the USA Executive & Director Changes stream (events March 23-27, 2026), a surge in C-level transitions (10+ CEO/CFO changes) and director resignations/not-for-re-election announcements (20+ instances) signals portfolio-wide leadership churn, predominantly neutral with no disagreements cited in 95% of cases. Positive hires in growth-oriented firms like Rumble (AI-savvy CFO), Sturm Ruger (finance transformation expert CFO), MaxCyte (20+ yrs finance CFO), and NCLH (new CEO with $48M equity package tied to TSR CAGR >5-20%) highlight conviction in scaling amid sector tailwinds; negative outlier in Nuwellis (director resignations citing info access disputes). No broad period-over-period financial deterioration evident, but 2026 incentive plans reveal forward thresholds like JAKKS EBITDA >$35.6M (tiered up to $65.6M max bonus), Fuel Tech OI >$250K pool funding, First Industrial FFO/NOI targets (55/30% weighting), implying stable-to-modest growth expectations absent YoY declines. Activist-driven board refreshes (e.g., NCLH/Elliott adding 5 independents) and planned retirements (e.g., SBA EVP Dec 2026) dominate, with mixed comp signals like Traeger discretionary bonuses despite 2025 misses. Implications: Monitor interim leadership risks in biotechs/fintech; bullish for cruise/tech with strong hires; sector churn neutral but flags governance watch in small-caps.

50 high priority 50 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 27, 2026

Across 50 SEC filings on USA Board Room Changes dated March 27, 2026, the dominant theme is elevated executive and board turnover, with 22 resignations/terminations/non-re-elections (44%), 18 appointments/promotions (36%), and 10 compensation/plan updates (20%), signaling transitional instability particularly in biotech/pharma (12/50 filings) and small-caps. Sentiment skews neutral (80%), with positive tones on strategic hires (e.g., Rumble CFO from Intel, Sturm Ruger CFO transition) and mixed/negative on sudden exits (e.g., Cue Biopharma CEO, Nuwellis director disputes). No explicit YoY/QoQ financial deteriorations noted, but interim leadership in 8 cases (e.g., One World, Reed's, Genesco) flags potential execution risks amid bonus plans tied to EBITDA/FFO targets in 5 firms. Activist-driven changes at NCL (board expansion to 9, 4 resign/5 appoint) highlight governance shakeups. Portfolio implications: Monitor small-cap biotechs for volatility; positive hires suggest growth conviction in tech/industrials. Overall, 14 high-materiality events (7-9/10) warrant near-term scrutiny for stock catalysts around AGMs.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 26, 2026

Across 50 DEF 14A proxy statements filed around March 26, 2026, a dominant theme is robust 2025 financial performance with 18/50 companies highlighting YoY revenue growth (avg +15% where quantified, e.g., Advanced Energy +21%, Liberty Media F1 +14%), record FCF in energy peers (CNX $646M, Peabody solid cash flow), and aggressive capital returns via buybacks ($3B Newmont, $528M CNX, 8% shares Banc CA) and dividend hikes (Oshkosh +11.8%, Hanover +5.6%). Exec comp is performance-aligned (79-95% at-risk/at equity in Tradeweb, Tractor Supply 89% variable), with high say-on-pay support (94.2% Eastern Bankshares, but KLX only 44.9%). Mixed signals in healthcare (Centene adj EPS $2.08 below outlook but 2026 >$3.00 +40% growth) and industrials (Oshkosh revenue -2.9% YoY). Governance strong: avg 85% board independence, diversity up (Tradeweb 55% indep, Invitation 40% diverse). No widespread insider selling noted; buybacks signal conviction. Portfolio trend: Bullish resource/energy (12/15 positive sentiment), neutral tech/healthcare; May 2026 meetings as catalysts for comp votes, declassifications.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — March 26, 2026

Across 43 filings on USA executive and director changes from March 26, 2026, the dominant theme is leadership transitions with 22 appointments (experienced hires in energy, tech, banking) versus 18 resignations/departures, mostly neutral sentiment but positive on strategic hires like Vitesse Energy's new CEO and Bloom Energy's CFO. Period-over-period data limited but notable: Interlink Electronics Q4 2025 revenue -4.5% YoY to $2.853M, gross margin -790 bps to 31.7%, though FY revenue +1.8% to $11.89M with net loss improved -19% to -$1.615M. No widespread insider trading or capital allocation shifts, but compensation enhancements (e.g., Meritage Homes CEO target $4M cash +$6M equity, Alight TVR awards up to 8.25M shares) signal retention focus. Positive hires boost conviction in growth sectors like AI/energy (Bloom, 3D Systems), while sudden CFO exits (RetinalGenix, MetroCity) flag risks. Portfolio implication: Monitor energy/utilities (6 filings) for stability, tech/biotech (12 filings) for innovation acceleration; overall neutral-to-positive for long-term value via succession planning.

43 high priority 43 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 26, 2026

Across 43 filings on USA Board Room Changes from March 26, 2026, the dominant theme is elevated C-suite and board turnover, with 18 CFO/CAO/Principal Accounting Officer changes (e.g., retirements, resignations, appointments), 12 CEO/President shifts, and 15+ board director additions/resignations/not standing for re-election, signaling proactive refreshes amid strategic pivots. Positive sentiment prevails in 12 cases (e.g., experienced hires in energy/tech like Vitesse CEO Jamie Benard, Bloom CFO Simon Edwards), neutral in 26, negative/mixed in 5, with materiality averaging 6/10 and peaking at 9/10 for Vitesse, Apimeds dispute, Skywater transaction. Sparse period-over-period data shows Interlink Electronics Q4 2025 revenue -4.5% YoY ($2.853M vs $2.986M), FY +1.8% ($11.89M), gross margins -780bps Q4/-260bps FY, highlighting product mix pressures; no broad deteriorating trends but isolated losses improving FY net loss -18.6% YoY. Forward-looking catalysts cluster around May 2026 AGMs (Macy's May 15, Auburn May 12) and Q2 transitions (Vitesse May 1 CEO). Portfolio implications: Bullish for leadership upgrades in growth sectors (energy, tech), bearish execution risks in finance CFO churn; monitor for insider conviction via post-change trading.

43 high priority 43 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 25, 2026

Across 50 DEF 14A proxy statements, a dominant theme is robust 2025 financial performance with 12 companies reporting YoY revenue growth averaging 14% (range 4-32%), including Amneal (8%), Century Communities ($4.1B total), Wyndham (rooms +4%), First BanCorp (record $1B, +15% NI), Goosehead (+16%), Sterling (32%), and Danaher ($24.6B sales). Capital returns were strong portfolio-wide, with 15 firms disclosing $10B+ aggregate returns via dividends/buybacks (e.g., Enact $500M, Wyndham $393M, 3M $4.8B, Ovintiv $600M, Allison $328M repurchases). Margin expansions noted in 7 cases (avg +120bps, e.g., Allison EBITDA +140bps, Wolverine adjusted op margin +70bps), while occupancy/volume gains in REITs/homebuilders (Regency +70bps shop occupancy). Mixed sentiments in 4 filings highlight challenges (Fox Factory profitability declines, Molson Coors missed top-line), but positive in 14; governance focuses on say-on-pay (all seeking approval post-strong perf) and plan expansions. Upcoming May 2026 meetings (45+ clustered May 4-14) serve as catalysts for comp votes, director elections, and stock plan approvals, signaling management alignment. Implications: Bullish for financials/REITs/energy/homebuilders; watch dilution risks in biotech/mining.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — March 25, 2026

Across 36 filings in the USA Executive & Director Changes stream, overarching themes include widespread board refreshes with 12 director retirements or non-re-elections timed to 2026 AGMs (e.g., ONEOK, Calumet, Civeo), 14 new appointments of experienced leaders in biotech, defense, and finance, and 8 C-level transitions marked by internal promotions or seamless handoffs. Period-over-period trends show mixed financial health: Maze Therapeutics cash doubled YoY to $360M (runway to 2028) but net loss widened to $131.1M from $52.2M profit; Generac reported $4.2B FY2025 sales and $716M Adjusted EBITDA (Residential +$558M). Neutral sentiment dominates (22/36 filings), with positive tones in growth sectors (biotech/defense 7/9 positive) signaling strategic enhancements amid no major disagreements. Critical developments like Muzinich BDC dual leadership overhaul (CEO/President/CFO changes April 1) and Six Flags' Executive Chairman appointment imply portfolio-level governance upgrades, potentially boosting operational execution. No broad insider trading patterns, but capital allocation leans retention-focused (e.g., QT Imaging 10% CEO salary hike, Middleby spin-off Q2 2026). Implications favor long-term stability over short-term volatility, with alpha in refreshed boards ahead of catalysts.

36 high priority 36 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 25, 2026

Across 36 SEC filings on USA Board Room Changes dated March 25, 2026, the dominant theme is executive and board turnover, with 18 resignations/retirements (e.g., Chairs, CFOs, directors) and 22 appointments/promotions, mostly neutral sentiment but positive in biotech (4/5) and finance (5/8). Period-over-period trends show mixed financial health: Generac FY2025 net sales $4.2B (implied strong YoY growth post-segments), Maze Therapeutics cash up 83% YoY to $360M (runway to 2028) despite net loss widening to $131.1M from $52.2M profit, no broad margin compression but R&D/G&A up 30-31% YoY in biotech. Insider activity absent, but capital allocation leans retention-focused (e.g., CEO extensions, RSU grants). Forward-looking catalysts cluster around 2026 AGMs (12+ retirements), Phase 2 trials (Maze mid/H2 2026), and spin-offs (Middleby Q2 2026). Portfolio-level pattern: internal promotions (7/22 appointments) signal continuity amid refreshes, bullish for stability in transforming sectors like midstream energy and cybersecurity; bearish risks from sudden CFO gaps (4 cases). Market implications: opportunities in experienced hires boosting governance in biotech/defense, watch for AGM successor announcements.

36 high priority 36 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 24, 2026

Across 42 DEF 14A proxy statements filed on March 24, 2026, a dominant theme is robust 2025 financial performance in energy, materials, and insurance sectors, with 12/42 filings highlighting YoY growth in key metrics like production (Magnolia +11%), net income (Nicolet +22%, Hamilton $576.7M), and cash flow (Albemarle OCF +86%, Eastman $1B). Capital allocation trends show strong shareholder returns, including $1.9B repurchases at Arch, 75% FCF returned at Magnolia ($322M total), and Vulcan's $700M dividends/buybacks, amid 16th consecutive dividend raise at Eastman. Mixed signals emerge in logistics (CH Robinson revenues -8.4% YoY but EPS +25.1%; Expeditors ocean decline), while governance focuses on say-on-pay votes (all recommending approval) and director elections cluster in May 2026. Notable M&A includes American Water's $3.7B capex and Essential Utilities acquisition by Q1 2027 end, plus Albemarle's $670M divestitures closing March 2026. Portfolio-level, 18/42 filings report positive YoY trends (avg revenue/sales growth ~10% where disclosed), signaling sector rotation into resources; risks center on delistings (BNB PLUS) and reorgs (Digimarc). Upcoming virtual annual meetings (35+ in April-May 2026) serve as catalysts for comp alignment and governance votes, with neutral sentiment in 60% but positive in high-materiality resource names.

42 high priority 42 total filings
· daily

US Executive Officer Management Changes SEC — March 24, 2026

Across 37 filings on USA executive and director changes dated March 24, 2026, a dominant theme is CFO turnover, with 10+ cases including a cluster of 6 New Mountain entities (e.g., Guardian IV BDC, Finance Corp) where Kris Corbett resigned as CFO effective post-transition by May 29, 2026, signaling potential short-term reporting risks but no disagreements noted. Positive internal promotions and experienced external hires dominate (e.g., Rush Enterprises COO, Dollar General CEO succession, Twilio/eBay board adds), reflecting proactive leadership refreshes amid sector growth, while high-materiality shocks like Simon Property Group CEO David Simon's death (10/10 materiality) and Indaptus Therapeutics' 96% change of control highlight acute vulnerabilities. Velo3D stands out with enriched financials: FY2025 revenue +12% YoY to $46M but gross margins cratered to -16.1% from -5.1% due to $7M write-downs, offset by $60-70M 2026 guidance and cash build to $39M (+3,150% YoY). Portfolio-level trends show neutral-to-positive sentiment in 70% of filings, with board expansions (e.g., Camp4, eBay) and retention incentives (e.g., Brag House RSUs replacing options) indicating management conviction; however, disputed CFO exits (FOXO) and planned retirements (Chesapeake, Solventum) cluster in finance/utilities. Implications: Investors should prioritize smooth successions for alpha (e.g., retail/tech) while monitoring BDC/fintech transition risks for volatility. No broad margin compression but isolated deteriorations (Velo3D -1,135 bps QoQ Q4); capital allocation leans toward equity incentives over buybacks/dividends.

37 high priority 37 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 24, 2026

Across 37 US SEC filings on boardroom changes dated March 24, 2026, a dominant theme is CFO and executive churn, particularly in private credit/BDC entities (New Mountain group: 13-15,17,18,20 with Kris Corbett resignations effective May 29, 2026), signaling potential leadership transitions amid sector pressures. Positive internal promotions and experienced external hires prevail in 70% of cases (e.g., RUSH, QuidelOrtho, eBay, Twilio, Dycom, American Airlines, Dollar General), boosting sentiment and stability in industrials, tech, and retail. Critical developments include Simon Property Group's CEO passing (materiality 10/10, mixed sentiment) with immediate family succession, Bitcoin Depot's CEO swap to fintech veteran Alex Holmes (9/10), and Indaptus Therapeutics' 96% control shift via $11.2M preferred stock sale (9/10 mixed). Portfolio-level trends show neutral/mixed sentiment in 45% of filings due to retirements/resignations without disputes, but no broad financial deterioration except Velo3D's FY2025 gross margins plunging to -16.1% from -5.1% YoY despite 12% revenue growth to $46M. Market implications favor monitoring fintech/retail for continuity premiums, while BDC/fund churn raises execution risks; overall, 18 positive appointments signal management deepening amid economic uncertainty.

37 high priority 37 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 23, 2026

Across 48 DEF 14A proxy statements filed March 23, 2026, companies emphasize strong 2025 performance with average reported revenue growth of 8-20% YoY in 12/48 filings (e.g., AbbVie +8.5% to $61.2B, Gallagher +20.7% to $13.7B), robust capital returns including dividend increases (AbbVie to $1.73/share, Kimberly-Clark 54th consecutive year), and buybacks (RLJ $28.6M), alongside governance enhancements like declassifying boards (AbbVie, Regions) and enabling special meetings (Molina, Regions). Key trends include outperformance vs. benchmarks (Progressive 1.6x S&P TSR, CME record volumes +6% YoY), margin resilience in services/insurance, but declines in consumer goods (Kimberly-Clark sales -2.1% YoY) and hospitality (RLJ constrained RevPAR). Critical developments feature leadership transitions (Intel new CEO Lip-Bu Tan, Entegris David Reeder), SPAC mergers (TETE to RADB), and pending deals (Kimberly-Clark $32B Kenvue H2 2026), signaling M&A momentum. Portfolio-level patterns show positive sentiment in 60% of filings (healthcare/financials leading), with high materiality (7-9/10) in 15 firms highlighting pay-for-performance alignment (e.g., Enpro 130.5% payouts). Market implications: Bullish for growth sectors, monitor May 2026 meetings for say-on-pay support gauging comp conviction.

48 high priority 48 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 23, 2026

Across 38 US SEC filings dated March 23, 2026, focused on boardroom changes, a dominant theme emerges of strategic leadership successions and transitions, with 12 positive sentiment cases (e.g., orderly CEO handovers in 4 Gladstone entities), 15 neutral director retirements/resignations, and 5 negative/mixed signals amid operational challenges like missed milestones. No broad YoY revenue growth trends reported, but period comparisons highlight BioAtla's 2025 bonus misses (0% payout) vs retention incentives for 2026 milestones, contrasting with reaffirmed FY26 outlooks (Cardinal Health). Insider-like conviction shines in internal promotions (e.g., Oil States CFO to CEO, Crawford interim to permanent) signaling stability, while 7 CEO/CFO departures raise continuity risks. Portfolio-level pattern: Biotech/healthcare (8 filings) shows 50% turnover rate with mixed milestones; finance/REITs (10 filings) emphasize governance separations (Chairman/CEO split). Forward catalysts cluster Q2 2026 (earnings, AGMs, milestones), implying near-term volatility but alpha in smooth transitions. Capital allocation leans retention bonuses/RSUs over buybacks, with no dividend/split changes noted.

38 high priority 38 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 20, 2026

Across 50 DEF 14A proxy statements, a dominant theme is robust 2025 performance with 18 companies reporting YoY revenue growth averaging 10%+ (e.g., Ameriprise +6% rev/$18.2B, Goldman +9%/$58.3B, Inspire +14%/$912M, Eli Lilly $65.2B), strong EPS expansions (Goldman +27% to $51.32, Ameriprise +12% to $39.34), and margin improvements (Latham +320bps gross margins, Pentair +170bps adj ROS), though 6 showed declines like Avalon net income -76% YoY. Positive sentiment prevails in 22 filings (44%), mixed/neutral in 28, with no explicit insider selling but high ownership concentrations signaling alignment (e.g., Preformed Line 33% insiders). Capital allocation favors shareholders via dividend hikes (Ameriprise 21st consecutive +20% returns, Penske $182M buybacks/1.8% shares), buybacks, and LTIPs tied to CAGR targets. Portfolio-level trends highlight financials/healthcare outperformance vs industrials mixed results, with pay-for-performance evident (Cogent CEO 152% AWR target payout). AGMs cluster April 29-May 13, 2026 as key catalysts for comp votes, auditor ratifications, and equity plan amendments. Market implications: Buy dips in high-performers pre-vote, monitor pay scrutiny in decliners.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — March 20, 2026

Across 38 SEC filings on US executive and director changes dated March 20, 2026, the dominant theme is high C-suite and board turnover with 70% neutral sentiment, including 18 resignations/retirements (mostly voluntary, no disagreements cited except one), 12 appointments/promotions of experienced executives, and 5 salary/bonus adjustments signaling retention efforts. No widespread period-over-period financial deterioration evident, but isolated YoY EPS gains (e.g., Nu Skin) and equity grants contrast with severances totaling $810k+ across cases like Aeries ($265k), CleanCore ($500k), reAlpha ($46k). Biotech/pharma (Aquestive, AN2, Iovance) shows positive hires amid FDA catalysts, while tech (SMCI, Rigetti, Roblox) mixes promotions with legal risks and board exits. Portfolio-level pattern: 15 CFO/CIO changes suggest transition risks in growth sectors; insider conviction mixed with promotions (e.g., Kite Realty CFO) but concerns from disputes (APHP). Implications: Bullish for experienced hires in REITs/fintech, bearish for legal overhangs; watch Q2 2026 AGMs and successor searches for volatility.

38 high priority 38 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 20, 2026

Across 38 SEC 8-K filings on USA Board Room Changes from March 16-20, 2026, the dominant theme is high executive and director turnover, with 24 resignations/retirements (mostly neutral voluntary exits citing no disagreements) versus 14 appointments/promotions, signaling routine board refreshes amid stable operations but potential leadership gaps in tech, biotech, and financials. Positive hires bring deep sector expertise (e.g., ex-Coinbase CFO at Streamex, Dycom ex-CEO at Centuri), while negatives include a director resignation over financial planning disputes at American Picture House and a criminal indictment impacting Super Micro executives. No uniform period-over-period financial trends emerge as filings focus on governance, but isolated signals like Nu Skin's interim CFO crediting YoY EPS gains from cost cuts and BranchOut's retroactive salary hikes post-growth highlight pockets of operational strength. Materiality skews high (avg 6/10) for CEO/CFO shifts (12 cases), implying short-term execution risks but long-term strategic upgrades. Portfolio-level pattern: neutral sentiment in 70% of filings suggests low disruption risk, but watch clustered director retirements ahead of 2026 AGMs for governance evolution. Market implication: opportunities in experienced hire turnarounds, risks in unresolved successions.

38 high priority 38 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 19, 2026

Across 50 DEF 14A filings, a dominant theme is robust 2025 performance highlighted in 17 positive/mixed sentiment proxies (e.g., revenue records at Vericel +20% CAGR, Occidental $10.5B OCF, TechnipFMC backlog +15% YoY), contrasting neutral governance-focused disclosures in 33 closed-end funds and REITs; period-over-period trends show YoY improvements in cash flows (e.g., TechnipFMC FCF +113%), dividends (Aflac +5.2%, BorgWarner +55%), and buybacks ($3.5B at Aflac), with rare declines like Aflac net earnings -29.2% YoY and Tronox 60% dividend cut. Capital allocation leans shareholder-friendly with $4.8B returned at Aflac and debt reductions (Occidental -$4B principal), signaling financial health amid economic challenges. Board refreshments are common (e.g., Sabre to 10 members, GEHC down to 8), with high say-on-pay support (Brunswick 97%, Tronox 96% avg last 7 yrs). A May 2026 cluster of 20+ annual meetings forms a catalyst calendar for say-on-pay votes and governance shifts. Portfolio-level, energy/industrials outperform (avg TSR +10-14%) vs flat funds, implying rotation into performers ahead of meetings.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — March 19, 2026

Across 27 filings on USA Executive & Director Changes from March 19, 2026, the dominant theme is neutral board and executive transitions (20/27 neutral sentiment), with routine director retirements/not standing for reelection (e.g., MediaAlpha, TripAdvisor, Tidewater) citing personal reasons and no disagreements, signaling stability rather than distress. Positive appointments dominate in financial services and healthcare (CVS Health, RGA, Array Technologies), adding audit/financial experts amid growth strategies, while isolated financial declines appear in hospitality (RCI Hospitality revenues -5.5% YoY to $279.4M, Bombshells -29.2% YoY). Period-over-period trends show outliers like Byrna Technologies' revenue surge >500% from $17M in 2020 to $118M in 2025 and RCI's share repurchases reducing shares 14% YoY to 7.71M, but no broad portfolio-level deterioration; net income improvements (RCI +$7.8M YoY) offset revenue softness. Forward-looking elements include 2026 compensation plans tying pay to EBITDA/revenue (MediaAlpha 25% PRSUs, Tigo 75% Adj EBITDA), bonus pools (Mercantile $1.21M target), and multiple 2026 annual meetings as catalysts. Capital allocation leans toward retention bonuses and RSUs over dividends/buybacks, with RCI's $45.4M FCF flat YoY highlighting reinvestment potential. Overall, low materiality (avg 5.6/10) suggests limited immediate volatility, but positive hires signal conviction in fintech/healthcare sectors.

27 high priority 27 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 19, 2026

Across 27 filings in the USA Board Room Changes stream (March 19, 2026), the dominant theme is neutral board and executive transitions, with 15/27 involving resignations or non-re-elections not due to disagreements, signaling routine refreshment rather than distress. Positive appointments dominate in financial services and energy sectors (e.g., CVS Health, RGA, Array Technologies), adding expertise in finance, reinsurance, and renewables amid strategic growth needs. Limited period-over-period data shows mixed financial health: RCI Hospitality revenues declined 5.5% YoY to $279.4M with Adjusted EBITDA down to $52.6M in 4Q25, contrasting Byrna Technologies' revenue surge from $17M (2020) to $118M (2025, +500%). No widespread insider selling or buying noted, but capital allocation highlights include RCI's 14% share reduction via buybacks and executive bonus plans tied to metrics like revenue/EBITDA in Tigo Energy and Mercantile Bank. Forward-looking catalysts cluster around 2026 annual meetings for director replacements and scheduled departures (e.g., Clear Secure GC April 3). Overall, low materiality (avg 5.6/10) suggests stable governance with opportunities in expertise-driven boards, but watch hospitality for ongoing SSS declines (-4.4% 4Q25).

27 high priority 27 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 18, 2026

Across 41 DEF 14A proxy statements, a dominant theme is strong 2025 financial performance in energy/utilities (e.g., Vistra's $5.912B Adjusted EBITDA exceeding guidance by $112M, NRG's 167% AIP EBITDA attainment) and financials (Wells Fargo's $21.3B net income, 12.4% ROE), with portfolio-level YoY revenue/earnings growth in 12/15 metric-disclosing firms averaging +15%, though mixed in semis/oil services (Lattice GAAP NI -95% YoY). Capital returns shine with $1.6B+ repurchases/dividends in multiple (NRG $1.65B, California Resources $513M), signaling management conviction amid robust governance (no hedging/pledging common). Merger activity (Black Hills-NorthWestern, California Resources-Berry) and CEO transitions (NRG, Regal Rexnord) add catalysts, with 30+ virtual annual meetings in late April-May 2026 as key voting events for comp approvals (97% prior support at Vistra). Sentiment skews positive/neutral (28/41), but outliers like premium declines (Assured Guaranty GWP down YoY) flag sector pressures. Implications: Bullish for utilities/energy on returns/growth; monitor REITs/banks for comp votes influencing retention.

41 high priority 41 total filings